 
 
 
August 01, 2023 
 
To, 
Listing Department,  
National Stock Exchange of India Limited 
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, 
Bandra (E), Mumbai – 400051 
 
NSE Symbol: BALAXI 
 
Subject:  Business Responsibility and Sustainability Report for FY 2022-23 
 
Dear Sir/Madam, 
 
Please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) of 
Balaxi Pharmaceuticals Limited (“the Company”) for Financial Year 2022-23. BRSR forms 
part of the Annual Report 2022-23 of the Company. 
 
The BRSR along with the Annual Report 2022-23 is available on the website of the Company 
at: 
https://balaxipharma.in/assets/images/articles/Balaxi_Pharmaceuticals_AR_2023.pdf  
 
This is submitted pursuant to Regulation 34(2) of the SEBI (Listing Obligations and 
Disclosure Requirements) Regulations, 2015. 
 
This is for your information and records. 
 
Yours Faithfully, 
 
For Balaxi Pharmaceuticals Limited 
 
 
Udayan Shukla 
(Company Secretary & Compliance Officer) 
Membership No.: F11744 
 
Encl: As above 
 
 
 
Udayan 
Shukla
Digitally signed 
by Udayan Shukla 
Date: 2023.08.01 
11:04:15 +05'30'
Section A) General Disclosures 
I. 	
Details of the listed entity
1.	
Corporate Identity Number (CIN) of the Listed Entity
L25191TG1942PLC121598
2.	
Name of the Listed Entity
Balaxi Pharmaceuticals Limited
3.	
Year of incorporation
1942
4.	
Registered office address
Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase – 
III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) – 500096.
5.	
Corporate address
Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase – 
III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) – 500096.
6.	
E-mail
secretarial@balaxi.in 
7.	
Telephone
+91 40 23555300
8.	
Website
www.balaxipharma.in 
9.	
Financial year for which reporting is being done
April 2022 – March 2023
10.	
Name of the Stock Exchange(s) where shares are 
listed
National Stock Exchange of India Limited
11.	
Paid-up Capital
₹ 10,18,12,500/- (Rupees Ten Crore Eighteen Lakhs Twelve 
Thousand Five Hundred only)
12.	
Name and contact details (telephone, email address) 
of the person who may be contacted in case of any 
queries on the BRSR report
Mr. Udayan Shukla, Company Secretary and Compliance Officer
Telephone: +91 40 23555300
Email: secretarial@balaxi.in 
13.	
Reporting boundary - Are the disclosures under 
this report made on a standalone basis  (i.e. only for 
the entity) or on a consolidated basis (i.e. for the 
entity and all the entities which form a part of its 
consolidated financial statements, taken together)
The disclosures under this report are made on a Standalone 
basis.
II. 	
Product & Services
14. 	 Details of business activities (accounting for 90% of the turnover):
S No
Description of Main Activity 
Description of Business Activity 
% of turnover of the entity 
1.
Trading
International Wholesale Trading/ Distribution
100%
15. 	 Products/Services sold by the entity (accounting for 90% of the entity’s turnover 
S No
Product /Service
NIC Code 
% of the total turnover contributed  
1
Pharmaceutical Products
464
75.00
2
Branded Consumer Products
463
22.00
III. 	
Operations 
16. 	 Number of locations where plants an/or operations/offices of the entity are situated 
Location 
Number of Plants 
Number of Offices  
Total  
National 
-
1
1
International 
-
-
-
Business Responsibility & 
Sustainability Report
1
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
17. 	 Markets served by the entity:
a.	
Number of Locations 
Locations 
Number 
National (No of States)
0
International (No of Countries) 
8
b. 	
What is the contribution of exports as a percentage of the total turnover of the entity ? 
	
100%
c. 	
A brief on types of customers 
	
Distributors, Wholesalers and Retailers 
IV.	
EMPLOYEES
18.	
Details as at the end of Financial Year:
a.	
Employees and Workers (including differently abled):
SL No.
Particulars 
Total (A)
Male
Female 
No. ( B)
% ( B/A)
No. (C)
% ( C/A)
Employees 
1
Permanent (D)
51
42
82.35
09
17.65
2
Other than Permanent (E) 
-
-
-
-
-
3
Total Employees (D+E)
51
42
82.35
09
17.65
Workers 
4
Permanent (F)
-
-
-
-
-
5
Other than Permanent (G)
-
-
-
-
-
6
Total (F+G)
-
-
-
-
-
b.	
Differently Abled Employees & Workers 
SL No.
Particulars 
Total (A)
Male
Female 
No. ( B)
% ( B/A)
No. (C)
% ( C/A)
Differently Abled Employees 
1
Permanent (D)
-
-
-
-
-
2
Other than Permanent (E) 
-
-
-
-
-
3
Total Employees
(D+E)
-
-
-
-
-
Differently Abled Workers 
4
Permanent (F)
-
-
-
-
-
5
Other than Permanent (G)
-
-
-
-
-
6
Total (F+G)
-
-
-
-
-
19 	
Participation/Inclusion/Representation of Women 
Particulars 
Total (A)
No. and percentage of Females 
No.(B)
% ( B/A)
Board of Directors 
6
2
33.33
Key Management Personnel
4
0
-
2
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
20. 	 Turnover rate for permanent employees and workers.
Turnover Rate - FY2023
Turnover Rate – FY2022
Turnover Rate – FY2021
Male 
Female
Total
Male
Female
Total
Male
Female
Total
Permanent 
Employees 
17.5%
30.00%
20%
14.71%
Nil
11.36%
19.35%
11.11%
17.5%
Permanent 
Workers 
NA
NA
NA
NA
NA
NA
NA
NA
NA
V. 	
Holding, Subsidiary and Associate Companies ( Including joint ventures )
21.	
(a)	 Names of holding/subsidiary/associate companies/joint ventures 
S 
No.
Name of the holding / subsidiary 
/ associate companies / joint 
ventures (A) 
Indicate whether 
holding/ Subsidiary/ 
Associate/ Joint 
Venture
% of shares held 
by listed entity 
Does the entity indicated at column 
A, participate in the Business 
Responsibility initiatives of the listed 
entity? (Yes/No) 
1.
Balaxi Overseas Private Limited
Holding Company
Not Applicable
No
2.
Balaxi Global DMCC, Dubai
Wholly Owned 
Subsidiary
100%
No
3.
Balaxi Healthcare Guatemala, S.A, 
Republic of Guatemala
Wholly Owned Step-
Down Subsidiary
100%
No
4.
Balaxi Healthcare Dominicana, 
S.R.L, Dominican Republic
Wholly Owned Step-
Down Subsidiary
100%
No
5.
Balaxi Healthcare Honduras, S. 
DE R.L. DE C.V, Honduras
Wholly Owned Step-
Down Subsidiary
100%
No
6.
Balaxi Healthcare Centrafrique, 
SARL, Centrafrique
Wholly Owned Step-
Down Subsidiary
100%
No
7.
Balaxi Healthcare El Salvador S.A 
DE., El Salvador
Wholly Owned Step-
Down Subsidiary
100%
No
8.
Balaxi Healthcare Angola, 
Republic of Angola
Wholly Owned Step-
Down Subsidiary
100%
No
Note: Balaxi Global DMCC, Dubai, Wholly Owned Subsidiary of the Company holds 100% of shares in the step-down subsidiaries.
Balaxi Overseas Private Limited is Holding Company of the Company and it holds 68.75% of the total equity shares in the Company.
VI.	
CSR Details 
22	
(i)	 Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes
	
(ii)	 Turnover (In ₹ Lakhs): 10813.76
	
(iii)	Net worth (in ₹ Lakhs): 9210.65
3
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
VII.	 Transparency and Disclosures Compliances 
23.	
Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business 
Conduct:
Stakeholder 
Group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place. 
Yes/No 
If Yes, then provide 
web-link for grievance 
redress policy
FY2023
FY2022
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close 
of the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close 
of the year
Remarks
Communities
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
Investors 
(Other than 
Shareholders)
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
Shareholders
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
Employees
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
Customers
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
Value Chain 
Partners
Yes
https://balaxipharma.in/ 
corporate-policies
Nil
Nil
Nil
Nil
24. 	 Overview of the entity’s material responsible business conduct issues 
Indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that 
present a risk or an opportunity to your business, the rationale for identifying the same, approach to adapt or mitigate the risk 
along with its financial implications, as per the following format
SL 
No
Material Issue 
Identified 
Indicate 
whether 
Risk or 
Opportunity
Rationale for identifying risk or 
opportunity 
In case of risk 
approach to adapt 
or mitigate 
Financial implications of 
the risk or opportunity 
(Indicate positive or 
negative implications) 
1.
Carbon 
Footprint in 
Global Supply 
Chain
Risk
Climate change will result in 
stricter environmental regulations 
across sectors, this will increase 
transportation 
cost 
for 
the 
Company.
Ensuring Vendors/ 
CDMOs 
are 
in 
compliance 
with 
the 
applicable 
e n v i r o n m e n t a l 
standards.
Negative 
: 
Increased 
operating 
costs 
in 
meeting 
the 
environmental standards.
2.
Diversity and 
Inclusion
Opportunity
Foster a diverse and inclusive 
workplace that promotes equality, 
non-discrimination, 
and 
equal 
opportunities for all employees. 
This will lead to a good talent pool 
for the Company.
-
Positive Implication: The 
productivity will increase 
due to healthy work 
environment.
3.
Corporate 
Governance
Opportunity
Ensuring good governance and 
transparent practices can help 
securing 
stakeholder 
interest, 
a higher reputation, reduced 
risks 
and 
improved 
financial 
performance.
-
Positive 
Implication: 
Reduced Risk due to 
transparent practices.
4
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
SECTION B: Management and Process Disclosures
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the 
NGRBC Principles and Core Elements.
Disclosure Questions 
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and Management Processes 
1. a.	 Whether your entity’s policy/policies cover 
each principle and its core elements of the 
NGRBCs. (Yes/No) 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
    b.	 Has the policy been approved by the Board? 
(Yes/No) 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
    c.	 Web Link of the Policies, if available 
https://balaxipharma.in/corporate-policies 
2.	
Whether the entity has translated the policy 
into procedures. (Yes / No) 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
3.	
Do the enlisted policies extend to your value 
chain partners? (Yes/No) 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
4.	
Name of the national and international 
codes/certifications/labels/ standards (e.g. 
Forest 
Stewardship 
Council, 
Fairtrade, 
Rainforest Alliance, Trustea) standards (e.g. 
SA 8000, OHSAS, ISO, BIS) adopted by your 
entity and mapped to each principle.
None
5.	
Specific commitments, goals and targets set 
by the entity with defined timelines, if any.
The Company is determined to follow the path envisioned under the 
9 principles laid down in the National Voluntary Guidelines on Social, 
Environmental & Economic Responsibilities of Business issued by the 
Ministry of Corporate Affairs.
6.	
Performance of the entity against the 
specific commitments, goals and targets 
along-with reasons in case the same are not 
met.
The Company shall continue to monitor its performance against the said 
principle(s) and take necessary action as and when the need arises.
Governance, leadership and oversight
7.	
Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets 
and achievements (listed entity has flexibility regarding the placement of this disclosure): 
	
The purpose of our business is to dedicatedly serve to ensure stakeholder delight and influence the environment and 
society at large with our good work, as we abide by our values that form the cornerstone of our business strategies, 
decisions, and activities. We are committed to this roadmap as we seek to grow sustainably and deliver Pharmaceutical 
Products to frontier markers with excellence, again and again, with a lot more rigor and enthusiasm as the days pass. 
8.	
Details of the highest authority responsible 
for implementation and oversight of the 
Business Responsibility policy (ies). 
Mr. Ashish Maheshwari (DIN: 01575984), Managing Director
Telephone: +91 40 23555300
Email: secretarial@balaxi.in 
9.	
Does the entity have a specified Committee of 
the Board/ Director responsible for decision 
making on sustainability related issues? (Yes / 
No). 
	
If yes, provide details. 
Yes, Committee consists of Managing Director as Chairman along with 
other functional heads.
5
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
10.	
Details of Review of NGRBCs by the Company:
Subject  for Review 
Indicate whether review was undertaken 
by Director / Committee of the Board/ Any 
other Committee
Frequency
(Annually/ Half yearly/ Quarterly/ Any other 
– please specify)
P1
P2
P3
P4
P5
P6
P7
P8
P9
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance 
against 
above policies and follow 
up action
Review was undertaken  
by the Managing Director
Half Yearly
Compliance with statutory 
requirements of relevance 
to the principles, and, 
rectification of any non-
compliances
Review was undertaken  
by the Managing Director
Quarterly
11.	 Has the entity carried out independent assessment/ evaluation of the 
working of its policies by an external agency? (Yes/No). If yes, Name 
of the agency.
P1
P2
P3
P4
P5
P6
P7
P8
P9
N
N
N
N
N
N
N
N
N
12. 	 If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: 
Questions 
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the Principles material to its business 
(Yes/No)
NA
NA
NA
NA
NA
NA
NA
NA
NA
The entity is not at a stage where it is in a position to formulate and 
implement the policies on specified principles (Yes/No)
NA
The entity does not have the financial or/human and technical 
resources available for the task (Yes/No)
NA
NA
NA
NA
NA
NA
NA
NA
NA
It is planned to be done in the next financial year (Yes/No)
NA
NA
NA
NA
NA
NA
NA
NA
NA
Any other reason (please specify)
 NA
SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE 
This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key 
processes and decisions. The information sought is categorized as “Essential” and “Leadership”. While the essential indicators 
are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily 
disclosed by entities which aspire to progress to a higher level in their quest to be  socially, environmentally and ethically 
responsible.
Principle 1. Businesses should Conduct and Govern themselves with integrity and in a manner that is ethical, transparent 
and accountable.
Essential Indicators: 
1. 	
Percentage coverage by training and awareness programmes on any of the Principles during the financial year: 
Segment 
Total Number of 
training and awareness 
programmes held 
Topics / principles covered under the 
training and its impact 
% of persons in respective 
category covered by the 
awareness programmes 
Board of Directors 
1
Anti Bribery and Anti Corruption Policy
100%
Key Managerial Personnel 
1
Anti Bribery and Anti Corruption Policy
100%
Employees other than BoD 
and KMPs
4
Anti Bribery and Anti Corruption Policy
POSH Act
Grievance Redressal Mechanism
Importance of Stakeholders
100%
Workers 
Not Applicable
2. 	
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the 
entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the 
following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI 
(Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity’s website):
6
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
A.	
Monetary 
Particulars 
NGRBC 
Principle
Name of the regulatory /
Enforcement  agencies/
judicial institutions 
Amount 
(In ₹)
Brief of the 
Case
Has an appeal been 
preferred ?
(Yes/No
Penalty/Fine
Nil
Nil
Nil
Nil
Nil
Settlement 
Nil
Nil
Nil
Nil
Nil
Compounding Fee 
Nil
Nil
Nil
Nil
Nil
B.	
Non Monetary 
Particulars 
NGRBC Principle
Name of the regulatory /
Enforcement  agencies/judicial 
institutions 
Brief of the Case
Has an appeal been 
preferred ? 
Yes/No
Imprisonment 
Nil
Nil
Nil
Nil
Punishment 
Nil
Nil
Nil
Nil
3.	
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision are preferred in cases where monetary or 
non-monetary action has been appealed. 
Case Details 
Name of the regulatory /enforcement agencies/judicial institutions 
Not Applicable
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, details in brief and if available, a web-link to the 
policy. 
	
Yes, Company have an anti – corruption and anti-bribery policy, Company recognises and follows all applicable laws and 
regulations and respects lawful customs of the regions where we operate and transact. We are committed to acting and 
building relationships based on integrity and fairness in all our dealings. Hence, Balaxi has adopted a “Zero Tolerance” 
approach to bribery and corruption. The policy is available on the website of the company at https://balaxipharma.in/
corporate-policies. 
5. 	
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement 
agency for the charges of bribery/ corruption: 
FY2023
FY2022
Directors 
Nil
Nil
KMPs
Nil
Nil
Employees 
Nil
Nil
Workers 
NA
NA
6.	
Details of complaints with regard to conflict of interest
Particulars 
FY2023
FY2022
Number
Remarks 
Number
Remarks 
Number of complaints received in relation to issues 
of Conflict of Interest of the Directors
-
-
-
-
Number of complaints received in relation to issues 
of Conflict of Interest of the KMPs
-
-
-
-
7.	
Details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law 
enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.: 
	
Not Applicable
7
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
Principle 2. Businesses should provide goods and services in a manner that is sustainable and safe.
Essential Indicators:
1.	
Percentage of R&D and capital expenditure (CAPEX) investments in specific technologies to improve the environmental 
and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.
Category 
FY2023
FY2022
Details of improvements in environmental and social impacts
R&D
Nil*
Nil*
-
Capex 
Nil*
Nil*
-
* As on March 31, 2023, the Company is operating on an asset-light model and hence, no capex has been incurred by the 
Company. 
2.	
Sustainable Sourcing 
a.	
Does the entity have procedures in place for sustainable sourcing? (Yes/No) 
	
Yes, We source from GMP Certified Contract Development Manufacturing Organisations (“CDMOs”).
b.	
If yes, what percentage of inputs were sourced sustainably? 
	
100% of our products are sourced from GMP Certified CDMOs.
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for
a.	
Plastics (Including Packaging): Yes
b.	
E- Waste: Yes
c.	
Hazardous Waste: Yes
d.	
Other Waste: Yes
	
We ensure the products are disposed off/ reused/ recycled, as per the nature of the product at the end of the life cycle 
in respective markets. 
4.	
Extended Producer Responsibility (EPR)
	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, whether the 
waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control 
Boards? If not, steps taken to address the same. 
	
Not Applicable, Company is not involved in any manufacturing activity. The Company is engaged in the business of 
International Wholesale Distribution in various international markets.
Principle 3. Businesses should respect and promote the well-being of all employees, including those in their value chains.
1.	
Essential Indicators:
a. 	
Details of measures for the well-being of employees 
Category
% of employees covered by
Total  
(A)
Health Insurance
Accident 
insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Number 
(B)
% 
(B/A)
Number 
(C)
%
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent Employees
Male
42
42
100
42
100
-
-
42
100
0
0
Female
09
09
100
09
100
09
100
-
-
0
0
Total 
51
51
100
51
100
09
17.65
42
82.35
0
0
Other than permanent employees
Male
0
0
0
0
0
-
-
0
0
0
0
Female 
0
0
0
0
0
0
0
-
-
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
8
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
b. 	
Details of measures for the well-being of Workers 
Category
% of workers covered by
Total  
(A)
Health Insurance
Accident 
insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Number 
(B)
% 
(B/A)
Number 
(C)
%
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent workers
Male
0
0
0
0
0
-
-
0
0
0
0
Female
0
0
0
0
0
0
0
-
-
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
Other than permanent workers 
Male
0
0
0
0
0
-
-
0
0
0
0
Female 
0
0
0
0
0
0
0
-
-
0
0
Total 
0
0
0
0
0
0
0
0
0
0
0
2.	
Details of retirement benefits, for current FY and previous financial year  
Benefits 
FY 2023 
FY 2022 
Number of 
employees 
covered as 
% of total 
employees 
Number of 
Workers 
covered as 
% of total 
workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A)
Number of 
employees 
covered as 
% of total 
employees 
Number of 
Workers 
covered as 
% of total 
workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A)
PF
100%
NA
Yes
100%
NA
Yes
Gratuity 
100%
NA
Yes
100%
NA
Yes
ESI
17.65%
NA
Yes
26.53%
NA
Yes
Others – specify 
-
-
-
-
-
-
3. 	
Accessibility of workplaces 
	
Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of 
the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard:
	
Yes, the office of the Company is accessible to differently abled employees.
4. 	
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so,  a web-link 
to the policy. 
	
Yes, the policy is available on the website of the company at https://balaxipharma.in/corporate-policies.
5. 	
Return to work and Retention rates of permanent employees and workers that took parental leave. 
Gender 
Permanent Employees 
Permanent Workers  
Return to work Rate 
Retention Rate
Return to work Rate 
Retention rate 
Male 
100%
100%
NA
NA
Female
-
-
NA
NA
Total 
100%
100%
NA
NA
Note: Only 1 Male Employee availed parental leave during the year.
9
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
6.	
Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? 
If yes, give details of the mechanism in brief.
Yes/No ( if yes then give details of the mechanism in brief) :
Permanent Workers 
Not Applicable
Other than Permanent Workers 
Not Applicable
Permanent Employees 
Yes, 
The Company has a Grievance Redressal policy, which address all kinds of issues an 
employee may face while at work. The grievance may include:
•	
Any kind of discrimination on account of disability, gender, race, sexual 
orientation, religion, marital status and social class
•	
Violation of human rights
•	
Bullying / workplace harassment
•	
Denial of applicable benefits
•	
Working conditions 
Other than permanent Employees 
Not Applicable
7. 	
Membership of employees and worker in association(s) or Unions recognised by the listed entity:
Category 
FY2023
FY2022
Total 
employees
/workers in 
respective 
category (A)
Total employees/
workers in respective 
category, who are part of 
association (s) or Union 
(s) (B)
% (B/A)
Total 
employees
/workers in 
respective 
category (C)
Total employees/
workers in respective 
category, who are part of 
association (s) or Union 
(s) (D)
% (D/C)
Total Permanent Employees 
Male 
42
0
0
38
0
0
Female 
9
0
0
11
0
0
Total Permanent Workers 
Male 
NA
NA
-
NA
NA
-
Female 
NA
NA
-
NA
NA
-
8. 	
Details of training given to employees and workers
Category
FY2023
FY2022
Total (A)
On health and 
safety Measures
On skill 
upgradation
Total 
(D)
On health and 
safety Measures
On skill upgradation
NO. (B)
% (B/A)
No. (C)
% (C/A)
No. (E)
% (E/D)
No.(F)
%(F/D)
Employees
Male
42
42
100
42
100
38
38
100
38
100
Female
9
9
100
9
100
11
11
100
11
100
Total
51
51
100
51
100
49
49
100
49
100
Workers
Male
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Female
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Total
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
10
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
9. 	
Details of performance and career development reviews of employees and workers:
Category
FY2023
FY2022
Total (A)
No.(B)
% (B/A)
Total (C)
No.(D)
% (D/C)
Employees
Male 
42
42
100
38
38
100
Female 
09
09
100
11
11
100
Total 
51
51
100
49
49
100
Workers
Male
NA
NA
NA
NA
NA
NA
Female 
NA
NA
NA
NA
NA
NA
Total 
NA
NA
NA
NA
NA
NA
10. 	 Health and safety management system
a. 	
Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If 
yes, the coverage such system? 
	
Yes, Company has implemented the Health and Safety Policy which covers all the employees of the Company.
b. 	
What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis 
by the entity? 
	
Appropriate policies / guidelines have been formulated to address various types of hazards and related risk 
assessment & mitigation.
-	
All work-related hazards are identified basis the recommended guidelines.
-	
Their associated risk assessment procedures are part of the Safety manual.
c. 	
Whether you have processes for workers to report the work related hazards and to remove themselves from such 
risks. (Y/N) 
	
Yes
d. 	
Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ 
No) 
	
Yes
11. 	 Details of safety related incidents, in the following format:
Safety Incident / Number 
Category 
FY2023
FY2022
Lost Time Injury Frequency Rate (LTIFR) Per One million 
-person hours worked 
Employees 
0
0
Workers 
NA
NA
Total recordable work-related injuries 
Employees 
0
0
Workers 
NA
NA
No of fatalities 
Employees 
0
0
Workers 
NA
NA
High consequence work-related injury or ill-health (excluding 
fatalities)
Employees 
0
0
Workers 
NA
NA
12. 	 Measures taken by the entity to ensure a safe and healthy work place.
	
Employee well-being programs/initiatives are conducted for all the employees and during FY 2022-23 the following well-
being initiatives were undertaken:
• 
Women safety programs
• 
Posh & gender sensitization meetings
• 
Road safety programs 
• 
Women self-defense program
• 
Fire emergency training exit
• 
General health check up
11
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
13.	
Number of Complaints on the following made by employees and workers:
FY2023
FY2022
Filed during 
the year 
Pending 
resolution at the 
end of the year 
Remarks 
Filed during 
the year 
Pending 
resolution at the 
end of the year 
Remarks 
Working Conditions
NIL
NIL
NIL
NIL
Health & Safety 
NIL
NIL
NIL
NIL
14. 	 Assessments for the year:
Particulars 
% of plants and offices that were assessed  
(By entity or statutory authorities or third parties 
Health and safety practices  
100%
Working Conditions 
100%
15.	
Details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / 
concerns arising from assessments of health & safety practices and working conditions.
	
The Company has implemented Hygiene Policy which ensures workplace cleanliness and basic amenities like availability 
of clean drinking water, proper sanitation facilities, etc. The HR team conducts review on a quarterly basis to ensure all 
the points under the hygiene policy are taken care of.
	
Further, Training of all employees regarding protocol to be followed in case of any safety incident has been conducted.
Principle 4. Businesses should respect the interests of and be responsive to all its stakeholders.
Essential Indicators:
1.	
Process for identification of key stakeholders
	
Balaxi, a pharmaceutical distribution company, effectively identifies its stakeholders through meticulous research and 
analysis. Senior management and HODs of the respective departments interact with the respective stakeholders before 
forming an association. Primary stakeholders such as customers, suppliers, employees, and investors are recognized, 
understanding their needs and expectations accordingly. The WHO GMP certified units from which Balaxi procures 
products are also considered stakeholders, ensuring high-quality standards. 
2.	
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/
No)
Channels of communication
(Email, SMS, Newspaper, Pamphlets, 
Advertisement, Community Meetings, 
Notice Board, Website), Other
Frequency of 
engagement
(Annually/ Half 
yearly/ Quarterly 
/ others – please 
specify)
Purpose and scope 
of engagement 
including key topics 
and concerns 
raised during such 
engagement
Customers 
(Distributors, 
Wholesalers and 
Retailers)
No
-	 satisfaction surveys
-	 Marketing and advertising
-	 Complaint handling and feedback 
-	 Electronic communication – social 
media, Calls
It is a continuous 
process
Addressing 
requirements 
for products and 
grievances, if any
Suppliers/
CDMOs
No
-	 Regular interaction through online 
and offline meetings, phone calls, 
e-mails
-	 Conferences and workshops
-	 In Person Meetings/ Visits.
Daily
To share the specific 
requirements, Status 
update on product 
deliveries and other 
terms of trade.
12
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/
No)
Channels of communication
(Email, SMS, Newspaper, Pamphlets, 
Advertisement, Community Meetings, 
Notice Board, Website), Other
Frequency of 
engagement
(Annually/ Half 
yearly/ Quarterly 
/ others – please 
specify)
Purpose and scope 
of engagement 
including key topics 
and concerns 
raised during such 
engagement
Employees
No
-	 Trainings 
and 
development 
programmes
-	 Performance management system
-	 Emails. Written communication
-	 circulars and internal publications
-	 Employee engagement initiatives
Daily/ Weekly
For smooth 
functioning of 
business operations.
Investors
No
-	 Annual General meeting
-	 Investor 
presentations 
and 
conference calls
-	 Investor conferences and meets
-	 Press releases, Quarterly Results and 
newsletters
Quarterly/ 
Annually/ Need 
basis
To provide updates on 
company’s operations 
and Financial 
Performance
Government/ 
Regulators
No
-	 Meetings and formal dialogue
-	 Filings with the regulators
Others – Need 
basis
Business and 
Compliance related 
Community
Yes
-	 CSR partnerships - Contribution 
towards various causes
Others – Need 
basis
CSR Initiatives of the 
Company
Principle 5. Businesses should respect and promote human rights 
Essential Indicators 
1.	
Employees and workers who have been provided training on human rights issues and  policy(ies) of the entity, in the 
following format: 
Category 
FY2023
FY2022
Total (A)
Number of 
employees 
and workers 
covered (B)
% (B/A)
Total (C)
Number of 
employees 
and workers 
covered (D)
% (D/C)
Employees
Permanent 
51
51
100
49
49
100
Other than Permanent 
0
0
-
0
0
-
Total Employees 
51
51
100
49
49
100
Workers
Permanent 
NA
NA
NA
NA
NA
NA
Other than permanent 
NA
NA
NA
NA
NA
NA
Total Workers 
NA
NA
NA
NA
NA
NA
13
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
2.	
Details of minimum wages paid to employees and workers, in the following format 
Category 
FY2023
FY2022
Total 
(A)
Equal to 
Minimum Wage 
More than 
Minimum Wage
Total 
(D)
Equal to 
Minimum Wage
More than 
minimum wage
No.(B)
%(B/A)
No.(C)
% (C/A)
No. (E)
% (E/D)
No.(F)
% (F/D)
Employees
Permanent 
Male
42
0
0
42
100
38
0
0
38
100
Female 
9
0
0
9
100
11
0
0
11
100
Other than 
Permanent 
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Workers
Permanent 
Male
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Female 
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Other than 
Permanent 
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Male
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Female
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.	
 Details of remuneration/salary/wages, in the following format:
Category 
Male 
Female 
Number 
Median remuneration/
salary/wages of 
respective category 
(Amt. in ₹ Lakhs)
Number 
Median remuneration/
salary/wages of 
respective category  
(Amt. in ₹ Lakhs)
Board of Directors
4
3.00
2
7.25
Key Managerial Personal 
4
30.25
-
-
Employees other than BoD and KMP
39
4.20
9
2.04
Workers 
NA
NA
NA
NA
*Note: Remuneration includes sitting fee paid to directors.
4. 	
Focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to 
by the business? (Yes/No) 
	
Yes
5. 	
Describe the internal mechanisms in place to redress grievances related to human rights issues.
	
Company is committed to providing a safe and positive work environment. In keeping with this philosophy, the organization 
has an open-door policy. Employees also have access to Human Resource Department where they can highlight matters or 
concerns faced at the workplace. This is achieved through a well-established and robust grievance resolution mechanism 
comprising of Internal Resolution Committee. Internal Resolution Committee adhere to the principles of natural justice, 
confidentiality, sensitivity, non-retaliation and fairness while addressing concerns. The concerns are handled with 
sensitivity, while delivering timely action and closure. 
14
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
6. 	
Number of Complaints on the following made by employees and workers:
Category 
FY2023
FY2022
Filed 
during 
the year 
Pending 
Resolution at 
the end of the 
year 
Remarks 
Filed 
During 
the Year 
Pending 
Resolution at 
the end of the 
year 
Remarks 
Sexual Harassment 
0
0
0
0
Discrimination at workplace 
0
0
0
0
Forced Labour/Involuntary Labour 
0
0
0
0
Wages
0
0
0
0
Other human right related issues 
0
0
0
0
7.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases. 
	
Yes, Company has mechanisms in place to prevent adverse consequences to the complainant in discrimination and 
harassment cases. The details of the complainant are kept confidential, and the authenticity of the complainant’s report is 
investigated by the assigned committee. The details regarding the investigation are also limited to the internal resolution 
committee and kept confidential. The complainant is protected from any discrimination and harassment till the issue is 
resolved. This is done in order to safeguard the complainant’s interest and confidence.
8.	
Do human rights requirements form part of your business agreements and contracts? (Yes/No) 
	
Yes
9.	
Assessments of the year
Category 
% of plants and offices that were assesses by the  
entity or by the statutory authorities or third parties  
Child Labour 
100%
Forced/Involuntary Labour 
100%
Sexual harassment 
100%
Discrimination at workplace 
100%
Wages 
100%
Others – please specify
NA
10. 	 Details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments 
at Question 9 above.
	
No significant risks reported in the assessment.
Principle 6. Businesses should respect and make efforts to protect and restore the environment. 
Essential Indicators:
1.	
Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:
Parameter 
FY23 (In Giga Joules)
FY22 (In Giga Joules)
Total electricity consumption (A) 
133.76
127.74
Total fuel consumption (B)
Nil
Nil
Energy consumption through other sources (C)
Nil
Nil
Total energy consumption (A+B+C) 
133.76
127.74
Energy intensity per rupee of turnover 
(Total energy consumption/ turnover in rupees)
0.012 GJ/ Rs. Lakhs
0.013 GJ/Rs. Lakhs
Energy intensity (optional) – the relevant metric may be selected by the entity
NA
NA
Any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the 
external agency. 
No
15
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
2.	
Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and 
Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have 
been achieved. In case targets have not been achieved, provide the remedial action taken, if any
	
No
3.	
Provide details of the following disclosures related to water, in the following format
Parameter 
FY23
FY22
Water Withdrawal by Source ( In Kiloliters ) 
(i)	
Surface water
NA
NA
(ii)	
Groundwater
-
-
(iii)	
Third party water
567
838
(iv)	
Seawater / desalinated water
-
-
(v)	
Others
-
-
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
567
838
Total volume of water consumption (in kilolitres)
567
838
Water intensity per rupee of turnover (Water consumed / turnover)
0.05 Kl/Rs. Lakhs
0.08 Kl/ Rs. Lakhs
Water intensity (optional) – the relevant metric may be selected by the entity
NA
NA
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency:
No
4. 	
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
	
Zero Liquid Discharge is not applicable to the Company as it is an International Wholesale Distribution Company and does 
not own any manufacturing plants.
5.	
Please provide details of air emissions (other than GHG emissions) by the entity, in the following format
Parameter
Please specify unit 
FY23
FY22
NOx
Nil
Nil
Sox
Nil
Nil
Particulate Mater 
Nil
Nil
Persistent organic pollutants (POP)
Nil
Nil
Volatile organic compounds (VOC)
Nil
Nil
Hazardous air pollutants (HAP)
Nil
Nil
Others – please specify 
Nil
Nil
The Company is not into manufacturing and therefore the possibility of releasing emissions into the atmosphere is negligible/
not applicable.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an  external agency? (Y/N) If yes, 
name of the external agency:
No
16
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
6.	
Details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & their intensity
Parameter 
Unit
FY23
FY22
Total Scope 1 emissions 
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of 
CO2 equivalent 
-
-
Total Scope 2 emissions 
(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) 
Metric tonnes of 
CO2 equivalent 
-
-
Total Scope 1 and Scope 2 emissions per rupee of turnover 
-
-
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric 
may be selected by the entity 
-
-
The Company is not into manufacturing and therefore the possibility of releasing greenhouse gas emissions into the atmosphere 
is negligible/not applicable.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Y/N) If yes, name of the external agency:
No
7.	
Project related to reducing Green House Gas emission? If yes, details.
	
No, the Company does not have any project related to reducing greenhouse gas emissions.
8.	
Provide details related to waste management by the entity, in the following format:
Parameter 
FY23
FY22
Total Waste generated (in metric tonnes)
Plastic waste ( A)
Nil
Nil
E-waste ( B)
Nil
Nil
Bio-medical waste ( C)
Nil
Nil
Construction and demolition waste (D)
Nil
Nil
Battery waste (E)
Nil
Nil
Radioactive waste (F)
Nil
Nil
Other Hazardous waste (G)
Nil
Nil
Other Non-hazardous waste generated (H)
(Break-up by composition i.e by materials relevant to the sector 
Nil
Nil
Total ( A+B+C+D+E+F+Gg+H)
Nil
Nil
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in 
metric tonnes) 
Category of waste 
i.	
Re-cycled 
Nil
Nil
ii.	
Re-used 
Nil
Nil
iii.	
Other recovery operations 
Nil
Nil
Total 
Nil
Nil
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes) 
Category of Waste 
i.	
Incineration
Nil
Nil
ii.	
Landfilling 
Nil
Nil
iii.	
Other disposal operations 
Nil
Nil
Total 
Nil
Nil
The nature of business of the Company is International Wholesale Distribution where Company does not have any manufacturing 
facility or produce anything inhouse and hence, this clause is not applicable to us.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency:
No
17
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
9.	
Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your 
company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to 
manage such wastes.
	
As an International Wholesale Distribution Company, we do not manufacture any products and thus does not use any 
hazardous or toxic chemicals. 
10.	
If the entity has operations/offices in/around ecologically sensitive areas (such as national  parks, wildlife sanctuaries, 
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals 
/ clearances are required,  please specify details in the following format:
Location of 
operations/offices 
Type of operations 
Whether the conditions of environmental approval / clearance are 
being complied with? (Y/N) 
If no, the reasons thereof and corrective action taken, if any. 
Not Applicable
Not Applicable
Not Applicable
11.	
Details of environmental impact assessments (EIA) of projects undertaken by the entity based on applicable laws, in the 
current financial year:
	
During the reporting period, Company has not conducted any environment impact assessment. Company ensures 
compliance to local and national applicable laws wherever required.
Name and brief 
details of project 
EIA 
Notification 
No.
Date
Whether conducted by 
independent external 
agency (Yes / No) 
Results communicated 
in public domain 
(Yes / No) 
Relevant Web 
Link  
Not Applicable
12.	
Compliance with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and 
Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder 
(Y/N). 
	
Yes, Company ensures compliance to applicable laws.
	
If not,  details of all such non-compliances, in the following format
SL 
No
Law / regulation / 
guidelines which was not 
complied with 
Details of the non-
compliance 
Any fines / penalties / action taken by 
regulatory agencies such as pollution 
control boards or by courts
Corrective action  
taken, if any 
Not Applicable
Principle 7. Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible 
and transparent.
Essential Indicators 
1 a.	 Number of affiliations with trade and industry chambers/associations: 5
   b.	 List the top 10 trade and industry chambers/associations (determined based on the total members of such body) the 
entity is a member of /affiliated to 
SL 
No
Name of the trade industry chambers/associations 
The reach of trade and industry 
chambers/associations (State/National) 
1
Two Star Export House Certificate by Directorate General of Foreign trade
National
2
Pharmexcil Registration from Pharmaceuticals Export Promotion Council 
of India
National
3
FSSAI Certification from Food Safety and Standards Authority of India 
(FSSAI)
National
4
Certification from Agricultural and Processed Food Products Export 
Development Authority (APEDA)
National
5
Member of Federation of Indian Export Organisation (FIEO)
National
18
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
2.	
Details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on 
adverse orders from regular authorities.
Name of authority 
Brief of the case 
Corrective actions taken 
Nil
Principle 8. Businesses should promote inclusive growth and equitable development 
Essential Indicators
1.	
Details of social impact assessments ( SIA ) of projects undertaken by the entity based on applicable laws, in the current 
financial year.
Name and brief 
details of the 
project
SIA 
notification 
No.
Date of 
notification 
Whether conducted by 
an Independent external 
agency (Yes/No) 
Results communicated in 
public domain (Yes/ No) 
Relevant 
weblink 
Not Applicable
2. 	
Information on project (s) for which ongoing rehabilitation and resettlement ( R&R) is being undertaken by the  entity
SL 
No
Name of  project for 
which R&R is ongoing 
State 
District  
No. of project-affected 
families  
% of PAFs 
covered by R&R
Amount paid to 
PAFs in FY23 
Not Applicable
3. 	
Mechanisms to receive and redress grievances of the community: 
	
We have a grievance redressal mechanism which covers all our stakeholders. Active engagement with the community 
and stakeholders requires an effective grievance redressal system that includes feedback loops and conflict resolution 
mechanisms. Stakeholders can share their feedback/ concern on info@balaxipharma.in
4. 	
Percentage of input material (inputs to total inputs by value) sourced from suppliers
Particulars 
FY23
FY22
Directly sourced from MSMEs/small producers
80.28%
72.20%
Sourced directly from within the district and neighbouring districts 
-
-
Principle 9. Businesses should engage with and provide value to their consumers in a responsible manner
Essential Indicators
1.	
Describe the mechanism in place to receive and respond to consumer complaints and feedback:
	
Consumers can directly contact the Company through email or phone and further our representative visits all the clients 
regularly for their feedback and issues, if any.
2.	
Turnover of products and /services as a percentage of turnover from all products/service that carry information about 
Particulars 
As a % of total turnover 
Environmental and social parameters relevant to the product 
100
Safe and responsible usage 
100
Recycling and/or safe disposal 
100
19
Corporate
Overview
Statutory
Reports
Financial
Statements
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
3.	
Number of consumer complaints in respect of the following 
Particulars 
FY2023
Remarks
FY2022
Remarks 
Received 
during the 
year 
Pending 
resolution at 
end of year
Received 
during the 
year 
Pending 
resolution at 
end of year
Data Privacy
0
0
0
0
Advertising
0
0
0
0
Cyber-security 
0
0
0
0
Delivery of essential services 
0
0
0
0
Restrictive Trade Practices 
0
0
0
0
Unfair Trade Practices 
0
0
0
0
Other 
0
0
0
0
4.	
Details of instances of product recalls on account of safety issues:
Particulars 
Number 
Reasons for recall 
Voluntary recalls 
0
N.A
Forced recalls 
0
N.A
5.	
Framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, web-link of the policy.: 
	
Yes, the policy is available at https://balaxipharma.in/corporate-policies.
6. 	
Details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; 
cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by 
regulatory authorities on safety of products / services.: 
	
None
20
Balaxi Pharmaceuticals Limited - Annual Report FY22-23
